Elanco set to acquire ChemGen as food demand becomes a top priority

Animal health firm Elanco is to acquire US bioscience firm ChemGen for an undisclosed amount.

Elanco is the animal health division of biotech giant Eli Lilly, which recently unveiled plans to build a new 22,000 sq ft facility at its operation in Dunderrow, Co Cork. The transaction is subject to customary US closing conditions.

Senior vice-president of Eli Lilly and president of Elanco Jeff Simmons said: “Meeting the growing demand for food is one of the most critical issues of our time. The acquisition of ChemGen and its premiere enzyme business further underscores Elanco’s commitment to provide our customers with leading animal productivity solutions